Bafna Pharmaceuticals share price
NSE: BAFNAPHBSE: 532989Pharmaceuticals & BiotechnologySmall Cap
Bafna Pharmaceuticals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 2008 on BSE, Apr 2018 on NSE
Last close ₹451.60up ₹8.85 (2.00%)BSE ₹458.65
Share price at the NSE close on 28 Oct 2026. Previous close ₹442.75.
28 Oct: open ₹451.60, high ₹451.60, low ₹451.60
52-week range of traded prices to 28 Oct 2026
₹94.77Low, 16 Mar 2026₹479.95High, 21 Oct 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,068 Cr2,105th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 137.21
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 11.11
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 8.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 4.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.39
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 11,610
Results
Standalone, as consolidated accounts are on record for only 4 of the last ten years; ₹ crore.Bafna Pharmaceuticals quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −3.1%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −5.8%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹27 Crdown 37.07%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹0.08 Crdown 97.27%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 0.3%
Revenue by quarter
Peak revenue ₹42 Cr, quarter to Mar 2026; lowest ₹27 Cr, quarter to Jun 2026
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 40.3 | 33.2 | 39.1 | 34.6 | 35.5 | 38.3 | 42.2 | 26.6 |
| Net profit | 2.6 | 0.9 | 1.3 | 3.4 | 3.1 | 1.8 | 2.7 | 0.1 |
| Net margin | 6.5% | 2.9% | 3.4% | 9.8% | 8.8% | 4.8% | 6.5% | 0.3% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹151 Crup 3.26%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹11 Crup 167.30%
- Net margin
- 7.4%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 4 of the 10 years shown
The years either side of a change of basis do not compare. From the year to Mar 2018, the company's revenue for that year, ₹47 Cr, differs from its quarters added, ₹77 Cr.
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65 | 47 | 43 | 42 | 71 | 85 | 115 | 152 | 146 | 151 |
| Net profit | −18 | −16 | −20 | −25 | 6 | 5 | 11 | 7 | 4 | 11 |
| Net margin | −28.4% | −34.9% | −45.5% | −59.3% | 8.2% | 6.1% | 9.8% | 4.8% | 2.8% | 7.4% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record.Bafna Pharmaceuticals PE ratio and valuation
Price to earnings
At or below today's level on 91% of 1,149 trading days over the last 5 years.
LowestHighest
Its median34.51Industry median27.98
Price to book
At or below today's level on 99.6% of 1,149 trading days over the last 5 years.
LowestHighest
Its median3.29Industry median2.94
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +46.2% | +166.5% | −45.1% | 0.0% |
| 3 years | +10.1% | −1.2% | +11.4% | 0.0% |
| 5 years | −4.5% | +13.8% | −16.0% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1 year includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the year to Mar 2025.
Bafna Pharmaceuticals competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Bafna Pharmaceuticals in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Fermenta BiotechFERMENTA | 1,303 | – | 3.21 | −3.2% | – | – | 13.5% | 0.85% |
 Anlon HealthcareAHCL | 1,301 | 44.76 | 5.65 | – | – | 13.9% | 18.0% | 0.00% |
 KopranKOPRAN | 1,220 | 48.83 | 2.30 | +12.0% | −28.4% | 4.8% | 6.2% | 1.19% |
 Lincoln PharmaceuticalsLINCOLN | 1,118 | 11.59 | 1.48 | +10.2% | +11.7% | 13.5% | 11.3% | 0.32% |
 Bajaj HealthcareBAJAJHCARE | 1,059 | 51.35 | 1.90 | +14.2% | −55.0% | 4.0% | 10.2% | 0.48% |
 Remus PharmaceuticalsREMUS | 1,030 | 27.85 | 2.94 | +37.6% | – | 12.2% | 13.1% | 0.11% |
 Sigachi IndustriesSIGACHI | 1,014 | 40.00 | 1.94 | −9.6% | – | 4.5% | 4.3% | 0.38% |
 Themis MedicareTHEMISMED | 907 | 22.68 | 2.27 | −12.8% | – | 10.0% | −10.5% | 0.51% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Bafna Pharmaceuticals dividend history
| Ex-date | Type | Per share |
|---|---|---|
| 19 Sep 2013 | Final | ₹0.60 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Bafna Pharmaceuticals announcements
Sep 2026
Aug 2026
Bafna Pharmaceuticals share price by year
Each calendar year to 2025.Bafna Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 150.72 | +91.0% | 192.44 | 70.97 |
| 2024 | 78.90 | −14.2% | 109.65 | 75.47 |
| 2023 | 92.00 | −8.7% | 124.45 | 79.85 |
| 2022 | 100.75 | −34.0% | 177.65 | 97.30 |
| 2021 | 152.55 | −10.7% | 186.80 | 112.90 |
| 2020 | 170.85 | +4,712.7% | 222.45 | 4.60 |
| 2019 | 3.55 | −69.3% | 12.00 | 3.55 |
| 2018BSE close | 11.55 | −58.8% | 30.10 | 10.85 |
| 2017BSE close | 28.00 | −2.8% | 33.45 | 22.40 |
| 2016BSE close | 28.80 | −36.0% | 50.45 | 26.95 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2020 is from its first session, 2 Mar 2020. The 2019 close is its last trade, on 23 Aug 2019.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 27 Oct 2026 | 442.75 | 442.75 | 442.75 | 442.75 | 442.75 | 4,915 |
| 26 Oct 2026 | 434.10 | 434.10 | 434.10 | 434.10 | 434.10 | 9,309 |
| 23 Oct 2026 | 442.95 | 442.95 | 442.95 | 442.95 | 442.95 | 1,422 |
| 22 Oct 2026 | 451.95 | 451.95 | 451.95 | 451.95 | 451.95 | 4,534 |
| 21 Oct 2026 | 479.95 | 479.95 | 461.15 | 461.15 | 469.13 | 19,261 |
| 19 Oct 2026 | 470.55 | 470.55 | 470.55 | 470.55 | 470.55 | 5,626 |
| 16 Oct 2026 | 460.00 | 461.35 | 460.00 | 461.35 | 460.20 | 20,755 |
| 15 Oct 2026 | 452.35 | 452.35 | 452.35 | 452.35 | 452.35 | 811 |
| 14 Oct 2026 | 443.50 | 443.50 | 443.50 | 443.50 | 443.50 | 2,305 |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Offer for sale history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 2 Mar 2020 | Price move | – | This is the share's first trade after a corporate action (Reduction of Capital, ex-date 26 Aug 2019), and the action's terms do not account for the move. Not adjusted for. |
Each event is noted and not adjusted for.
Company details
- NSE symbol
- BAFNAPH
- BSE code
- 532989
- ISIN
- INE878I01022
- Industry
- Pharmaceuticals & Biotechnology
- Former symbols
- BAFNAPHARM
- Website
- www.bafnapharma.com
- CIN
- L24294TN1995PLC030698
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1995
- Registered office
- Bafna Towers, 299, Thambu Chetty Street, Chennai 600001, Tamil Nadu
- Share registrar
- Cameo Corporate Services Ltd
- Keeps the register of shareholders and handles transfers and dividend payments